Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Publication | Open Access

DOI Full Paper Access

371

Citations

References

2018

Year

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Amanda E. Clarke, Chien‐Ching Hung, Jürgen K. Rockstroh, Pierre‐Marie Girard, Jörg Sievers,

The Lancet

Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical TrialsPharmacologyVirologyAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapyHiv-1 InfectionLamivudine Versus DolutegravirHivPublic HealthMedicineAntiviral DrugAids Pathogenesis